Linezolid: safety and efficacy in special populations.

Linezolid has been in general use in the UK since 2000. Although toxicity, particularly haematological and neurological, has been an issue, linezolid has proved to be an effective alternative to glycopeptides in the treatment of Gram-positive infections. Since its original licence for the treatment of skin and soft tissue infections and pneumonia, there have been reports of its successful use in the treatment of bone and joint infections, endocarditis, and other difficult-to-treat infections.

[1]  P. Tovo,et al.  Clinical experience with linezolid in infants and children. , 2011, The Journal of antimicrobial chemotherapy.

[2]  R. Wiener,et al.  Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. , 2011, Chest.

[3]  M. Rupp,et al.  Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis* , 2010, Critical care medicine.

[4]  C. Luna,et al.  Vancomycin, unbeatable for methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia? Really? , 2010, Critical care medicine.

[5]  D. Nathwani,et al.  Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections , 2010, Current medical research and opinion.

[6]  K. Itani,et al.  Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. , 2010, American journal of surgery.

[7]  R. Wiener,et al.  Linezolid Versus Glycopeptide Antibiotics In The Treatment Of Suspected Gram Positive Pneumonia: A Meta-Analysis Of Randomized Controlled Trials , 2010, Asian Test Symposium.

[8]  P. Selviaridis,et al.  Linezolid Penetration Into Cerebrospinal Fluid and Brain Tissue , 2010, Journal of chemotherapy.

[9]  C. López-Cabezas,et al.  Antibiotics in endophthalmitis: microbiological and pharmacokinetic considerations. , 2010, Current clinical pharmacology.

[10]  M. Bounthavong,et al.  Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis , 2010, Current medical research and opinion.

[11]  G. Papanicolaou,et al.  Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  D. Vinh,et al.  Linezolid: a review of safety and tolerability. , 2009, The Journal of infection.

[13]  M. Falagas,et al.  Linezolid for patients with neutropenia: are bacteriostatic agents appropriate? , 2009, Expert review of anti-infective therapy.

[14]  A. Fraise,et al.  Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. , 2009, The Journal of antimicrobial chemotherapy.

[15]  A. Adán,et al.  Pharmacokinetics of linezolid in human non-inflamed vitreous after systemic administration. , 2009, The Journal of antimicrobial chemotherapy.

[16]  D. Herr,et al.  Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  C. Cabellos,et al.  Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. , 2008, The Journal of infection.

[18]  T. Tsaganos,et al.  Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. , 2008, The Journal of antimicrobial chemotherapy.

[19]  A. Gascoigne,et al.  Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy , 2008, The Journal of antimicrobial chemotherapy.

[20]  Yen-Hung Lin,et al.  High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. , 2006, International journal of antimicrobial agents.

[21]  M. Falagas,et al.  Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. , 2006, The Journal of antimicrobial chemotherapy.

[22]  John W. Wilson,et al.  Linezolid and serotonergic drug interactions: a retrospective survey. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  A. Fraise,et al.  Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. , 2006, The Journal of antimicrobial chemotherapy.

[24]  G. Martinelli,et al.  Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Janet C. Rucker,et al.  Linezolid-associated toxic optic neuropathy , 2006, Neurology.

[26]  M. Bassetti,et al.  Linezolid in the treatment of Gram-positive prosthetic joint infections. , 2005, The Journal of antimicrobial chemotherapy.

[27]  Y. Yazdanpanah,et al.  Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. , 2004, The Journal of antimicrobial chemotherapy.

[28]  D. Osmon,et al.  Linezolid therapy for orthopedic infections. , 2004, Mayo Clinic proceedings.

[29]  I. Sia,et al.  Linezolid-associated peripheral neuropathy. , 2004, Mayo Clinic proceedings.

[30]  Y. Yazdanpanah,et al.  Linezolid-induced neuropathy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  H. Guggenberger,et al.  Treatment of Meningitis Due to Methicillin-Resistant Staphylococcus epidermidis with Linezolid , 2004, Journal of Clinical Microbiology.

[32]  D. Nathwani,et al.  Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. , 2004, The Journal of antimicrobial chemotherapy.

[33]  F. Warren,et al.  Linezolid-associated toxic optic neuropathy: a report of 2 cases. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  S. Kaplan,et al.  Hematologic effects of linezolid in young children , 2003, The Pediatric infectious disease journal.

[35]  S. Cammarata,et al.  Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies , 2003, Antimicrobial Agents and Chemotherapy.

[36]  Jerome J. Schentag,et al.  Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. , 2003, Annals of Oncology.

[37]  M. Wilcox.  Efficacy of linezolid versus comparator therapies in Gram-positive infections. , 2003, The Journal of antimicrobial chemotherapy.

[38]  G. French.  Safety and tolerability of linezolid. , 2003, The Journal of antimicrobial chemotherapy.

[39]  J. Caillon,et al.  In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. , 2003, The Journal of antimicrobial chemotherapy.

[40]  R. Rakita,et al.  Linezolid-induced lactic acidosis. , 2003, The New England journal of medicine.

[41]  M. Zervos,et al.  Thrombocytopenia associated with linezolid therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  P. Viale,et al.  Linezolid for the Treatment of Central Nervous System Infections in Neurosurgical Patients , 2002, Scandinavian journal of infectious diseases.

[43]  G. Tillotson,et al.  Hematologic Effects of Antimicrobials: Focus on the Oxazolidinone Linezolid , 2001, Pharmacotherapy.

[44]  F. K. Gould,et al.  Prosthetic joint infections: single versus combination therapy. , 2010, The Journal of antimicrobial chemotherapy.

[45]  W. Rui,et al.  Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. , 2010, International journal of antimicrobial agents.

[46]  M. Falagas,et al.  Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections , 2008, Drug safety.